IVVD (Invivyd, Inc. Common Stock)
Insider Trading Activity
Every open-market purchase and sale reported by IVVD officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-02 | Ian Sheffield | Director | A | — | — |
| 2026-09-01 | Marc Elia | Chief Executive Officer | A | — | — |
| 2026-08-18 | William E. Duke | Chief Financial Officer | MIXED | — | — |
| 2026-08-18 | Timothy Edward Lee | Chief Commercial Officer | MIXED | — | — |
| 2026-08-18 | Julie Green | Chief Human Resources Officer | MIXED | — | — |
| 2026-08-18 | Jill Andersen | Chief Legal Officer, Secretary | MIXED | — | — |
| 2026-08-18 | Robert D. Allen III | Chief Scientific Officer | MIXED | — | — |
| 2026-08-04 | Michael Mina | CMO and Chief Epidemiologist | A | — | — |
| 2026-05-21 | TERRANCE MCGUIRE | Director | A | — | — |
| 2026-05-21 | PAUL BOLNO | Director | A | — | — |
| 2026-05-21 | Ajay Royan | Director | A | — | — |
| 2026-05-21 | KEVIN F MCLAUGHLIN | Director | A | — | — |
| 2026-05-21 | M28 Capital Management LP | — | A | — | — |
| 2026-05-21 | Tamsin Berry | Director | A | — | — |
| 2026-02-18 | Jill Andersen | Chief Legal Officer, Secretary | MIXED | — | — |
| 2026-02-18 | Julie Green | Chief Human Resources Officer | MIXED | — | — |
| 2026-02-18 | Robert D. Allen III | Chief Scientific Officer | MIXED | — | — |
| 2026-02-18 | Timothy Edward Lee | Chief Commercial Officer | MIXED | — | — |
| 2026-02-18 | William E. Duke | Chief Financial Officer | MIXED | — | — |
| 2026-01-30 | William E. Duke | Chief Financial Officer | A | — | — |
| 2026-01-30 | Robert D. Allen III | Chief Scientific Officer | A | — | — |
| 2026-01-30 | Jill Andersen | Chief Legal Officer, Secretary | A | — | — |
| 2026-01-30 | Julie Green | Chief Human Resources Officer | A | — | — |
| 2026-01-30 | Timothy Edward Lee | Chief Commercial Officer | A | — | — |
| 2025-11-20 | KEVIN F MCLAUGHLIN | Director | Buy | — | — |
| 2025-09-24 | PAUL BOLNO | Director | A | — | — |
| 2025-08-19 | Jill Andersen | Chief Legal Officer, Secretary | MIXED | — | — |
| 2025-08-19 | Julie Green | Chief Human Resources Officer | MIXED | — | — |
| 2025-08-19 | William E. Duke | Chief Financial Officer | MIXED | — | — |
| 2025-08-19 | Timothy Edward Lee | Chief Commercial Officer | MIXED | — | — |
| 2025-08-19 | Robert D. Allen III | Chief Scientific Officer | MIXED | — | — |
| 2025-05-22 | KEVIN F MCLAUGHLIN | Director | A | — | — |
| 2025-05-22 | Christine Lindenboom | Director | A | — | — |
| 2025-05-22 | Tamsin Berry | Director | A | — | — |
| 2025-05-22 | Ajay Royan | Director | A | — | — |
| 2025-05-22 | TERRANCE MCGUIRE | Director | A | — | — |
| 2025-05-22 | M28 Capital Management LP | — | A | — | — |
| 2025-03-26 | Ajay Royan | Director | A | — | — |
| 2025-02-19 | Julie Green | Chief Human Resources Officer | A | — | — |
| 2025-02-19 | Timothy Edward Lee | Chief Commercial Officer | A | — | — |
| 2025-02-19 | Jill Andersen | Chief Legal Officer, Secretary | A | — | — |
| 2025-02-19 | Robert D. Allen III | Chief Scientific Officer | A | — | — |
| 2025-02-19 | William E. Duke | Chief Financial Officer | A | — | — |
| 2024-12-31 | TERRANCE MCGUIRE | Director | Sell | — | — |
| 2024-12-26 | TERRANCE MCGUIRE | Director | Sell | — | — |
| 2024-12-19 | TERRANCE MCGUIRE | Director | Sell | — | — |
| 2024-12-16 | TERRANCE MCGUIRE | Director | Sell | — | — |
| 2024-12-11 | TERRANCE MCGUIRE | Director | Sell | — | — |
| 2024-06-06 | Timothy Edward Lee | Chief Commercial Officer | A | — | — |
| 2024-05-31 | TERRANCE MCGUIRE | Director | Sell | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | 10%+ Owner | 21,687,906 | — |
| — | Director | 3,170,231 | — |
| — | Chief Legal Officer, Secretary | 352,236 | — |
| — | Chief Commercial Officer | 197,362 | — |
| — | Chief Scientific Officer | 195,808 | — |
| — | Chief Financial Officer | 168,937 | — |
| — | Chief Human Resources Officer | 168,937 | — |
| — | Director | 50,000 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the IVVD quote page; the site-wide leaderboard is on the insider transactions hub.